StemCell Therapy

The NIH Strategic plan focuses on "Precision Nutrition What to Eat to Stay Healthy." NIH in conjunction with the Nutrition Research Task Force will partner with private and public organizations to accelerate nutrition science with the focus on precision medicine. The ambitious initiative looks to push forward the concept of individualized dietary recommendations to maximize health as well as prevent and combat disease.

"We are thrilled to be recognized by NIH as a pioneer in the field of precision nutrition. We look forward to supporting and participating in the ongoing research effort toward new discoveries," said Lihi Segal, CEO and founder of DayTwo.

Metabolic disease (diabetes, prediabetes, clinical obesity and NASH) impacts almost 3/4 of U.S. adults and costs the U.S. economy almost $700 billion a year. In the era of COVID-19, people with diabetes rank first and second at risk for hospitalizations and death if they contract the disease. Poor nutrition is a root cause of metabolic disease and according to the American Diabetes Association, food choices are the greatest stressor and have the greatest impact on daily life for people with diabetes.

DayTwo was founded as a result of a clinical trial published in Cell in 2015 entitled, "Personalized Nutrition by Prediction of Glycemic Responses." A follow-up clinical trial was published in the Journal of the American Medical Association in 2019 entitled, "Assessment of a Personalized Approach to Predicting Postprandial Glycemic Responses to Food." Both studies demonstrated that people respond differently to the same food, and the personalized response can be predicted using machine learning algorithms based on high resolution, gut microbiome profiling and additional clinical and personal parameters.

Employers and payers looking to learn more can contact Robert Boyer, vice president of Enterprise Solutions, at [emailprotected]. Or, visit http://www.daytwo.com/employers.

About DayTwo DayTwo is the only precision nutrition solution that enables a path to remission for metabolic disease. DayTwo's telehealth-centric, high touch / high tech solution employs machine learning algorithms based high resolution gut microbiome profiling and additional clinical and personal parameters, a care team of Certified Diabetes Care and Educational Specialists / Registered Dietitian Nutritionists skilled in behavioral coaching and a digital app to achieve outcomes. DayTwo offers up to 100% fees at risk for its solution.

For questions or comments about this release please contact [emailprotected] 415-426-4767.

SOURCE DayTwo

https://www.daytwo.com

Go here to read the rest:
DayTwo Science Cited in 10-Year $150 Million National Institutes of Health Precision Nutrition Strategic Plan - PRNewswire

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive is pleased to announce it has partnered with The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers to host the 11th Annual Ruesch Center Symposium Nov. 20-21.

We are honored to be able to work with The Ruesch Center to help transition their annual symposium into a virtual, interactive learning experience during this uncertain time, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of OncLive. The Ruesch Center is part of our exclusive strategic alliance partnership program, and this is a great example of how we can use our state-of-the-art studio to still deliver critical information to the gastrointestinal cancer community.

The educational symposium brings together clinicians, researchers, patients, caregivers, policymakers and industry representatives to network and debate critical issues related to GI cancers. Throughout the two-day virtual meeting, expert speakers will participate in three educational sessions addressing topics such as innovations in therapeutics, cancer genetics and targeted therapies, nuclear imaging and therapy for neuroendocrine tumors, and precision medicine.

The sessions include the following:

As a special highlight, the symposium will offer access to watch the 2020 Luminary Awards in GI Cancers ceremony. The five honorees, Richard M. Goldberg, M.D.; Gayle S. Jameson, MSN, RN, ACNP-BC, AOCN; Stacie C. Lindsey; Tyvin Rich, M.D., FACR; and Diane M. Simeone, M.D., will be presented with their awards and honored for their dedication to improving care for patients and families who are affected by GI cancers.

Finding more cures for GI cancer will only come through innovative research, and we are so proud to be featuring both the most up-to-date science and the projects of tomorrow. And as a bonus, we will be premiering our new POWER program, a short course in precision medicine to close our knowledge gaps in this rapidly evolving field, said John L. Marshall, M.D., director, The Ruesch Center for the Cure of GI Cancers.

This symposium has been approved for up to 11 AMA PRA Category 1 Credits and ANCC contact hours.

For more information and to register, click here.

About OncLive

A digital platform of resources for practicing oncologists, OncLive offers oncology professionals information they can use to help provide the best patient care. OncLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About The Ruesch Center for the Cure of Gastrointestinal Cancers

The Ruesch Center for the Cure of Gastrointestinal Cancers is part of the Georgetown Lombardi Comprehensive Cancer Center. It focuses on personalized patient care and fighting against gastrointestinal cancers. The Ruesch Center provides the highest standard of care and individualized cures through clinical trials and research, education and advocacy, and regional and global alliances.

Go here to read the rest:
OncLive Partners with The Ruesch Center to Host the 11th Annual Ruesch Center Symposium - Business Wire

COVID-19 has led to rapid changes in health care innovation: telemedicine, artificial intelligence, payment models, and a host of other digital analytics tools have morphed from experimental to borderline conventional.

At a panel during the 2020 North Texas State of Reform Virtual Health Policy Conference, health executives Tom Banning, chief executive officer of Texas Academy of Family Physicians,Dr. Andrew Masica, senior vice president of Texas Health Resources, and Dr. Steve Miff, president of Parkland Center for Clinical Innovation, met to discuss which of these developments will last beyond the pandemic.

Before COVID-19, telemedicine accounted for about one percent of health care visits, approximately 1.4 million visits. According to Tom Banning, seven months later, the nation has seen a three-fold increase in the use of telemedicine, accounting for about 35 million virtual visits.

I dont think theres any question that telemedicine is here to stay, Banning says. Its proven its effectiveness. Patients now expect to be able to connect with their doctors, and doctors see value in connecting with their patients.

Despite the high reliance on telehealth during the pandemic, health executives like Banning acknowledge that there are still workflow and payment methodologies to develop for telemedicine to become a scalable and viable innovation long term.

I dont think theres any question that telemedicine is here to stay.

Through partnerships and collaboration across healthcare organizations, leaders have rapidly applied predictive analytics to engage with the surrounding community.Its kind of ironic. Data and computers are helping deliver more personalized medicine, Dr. Andrew Masica says. If we do it the right way, thats a possibility for health systems.

The pandemic laid bare the need for high-speed data reports that allow primary care physicians to understand and digest patient information quickly. Through this innovation, healthcare providers and physicians can better leverage data, creating more personal interactions with patients.

There has been a paradigm shift, Masica says. We know the market and patient expectations are going to be different. Our challenge is to adapt to whats at hand. The underlying theme of where digital tools and innovation can help us is the push towards a more consumer and patient-centered health system with the ability to leverage data in real-time.

The development of proximity data has been crucial to understanding the viruss spread and defining vulnerability indexes. Initially, health officials attempted to track the virus by monitoring Americans international travel. With the virus rapid spread across the nation and relatively high case counts months later, these data tools have provided health experts with predictive tools to anticipate the virus and critical areas of concern.

It gives us something very actionable to do, Dr. Miff says. Predictive modeling is pretty simple. Based on a patients address, we can geo-map every single positive case, and then use a sophisticated machine learning formula to calculate distances to those positive cases and the density.

As the industry adapts to changes in innovation, health leaders are regularly evaluating the outcomes of these new measures to determine their effectiveness outside of controlled trials. Moving beyond the pandemics initial peak, further study will be necessary for defining these tools future use.Proof of efficacy isnt proof of effectiveness, Masica says. We need to be adopting and pushing digital innovations that are shown to be effective and rigorously assessing the outcomes of these technologies.

See the original post:
COVID-19 Is Redefining Healthcare Innovation - D Healthcare Daily

The patient-physician relationship, foundational to the profession of medicine and healing, relies on open and honest dialogue and an unwavering trust that we are making decisions about our patients health and livelihoods free of undue influence or conflicts of interest. The same is true for our public health institutions and our health system at largeespecially in a time of great urgency and crisis.

During this COVID-19 pandemic, physicians are unfortunately fighting a two-front war. Already facing one of the greatest threats to public health in generations, we have been pulled into a public battle we did not want over the very legitimacy of our work and our motivation.

The assault on public health and the undermining of efforts to defeat COVID-19 began with unfounded suspicions about the science and evidence of this novel coronavirus and how it spreads. It grew with speculation about harmful and unproven treatments for COVID-19, false claims that masks were a source of infections, and by misleading suggestions that increased testing alone explains why case counts are surging.

It expanded again with inaccurate, dangerous statements about children being almost immune from the most serious effects of COVID-19, a reckless plan of focused protection and naturally acquired herd immunity as a pathway out of this pandemic, and most recently with wild and highly offensive claims that physicians are inflating the number of COVID-19 cases and deaths to increase our incomes.

At every turn, at the highest levels of government, our motives and efforts are undermined, questioned and discredited in a misguided attempt to downplay the seriousness of the pandemic we continue to fight.

Many physicians, nurses and other health care personnel have died, and many more have fallen ill, while treating our patients. Public health officials have been threatened and intimidated, prompting some to retire or quit critical positions. All have worked tirelessly and under considerable stress and strain to turn the tide against COVID-19. We know these numbers surely will grow in the weeks ahead as the accelerating pace of this pandemic places enormous pressure on our already crowded hospitals and front-line physicians and first responders.

A continued campaign of misinformation and disinformation at this urgent hour is an unconscionable betrayal of the public trust that jeopardizes our work and endangers lives.

The U.S. is rapidly approaching 9 million confirmed cases of COVID-19, far surpassing every other country on earth. More than 225,000 of our fellow citizens have died and thousands more cling to life in crowded intensive care units across the country as cases surge ever higher.

Soon we will enter another critical period of this pandemic, a time when we will ask the public to trust the work of scientists, researchers and physicians, and get vaccinated against this virus.

A safe and effective COVID-19 vaccine will be a remarkable feat, and a true turning point in the pandemic. The language we use about this accelerated process and the checks and balances meant to ensure safety and efficacy is critical. We cannot afford to lose the faith of our patients. Not when so much death and suffering has already occurred. Not when physiciansand our entire health care communityhave already paid so steep a price.

Our AMA will always stand on the side of patients and physicians, of science and evidence, and of free and honest conversations that build the trust that is so crucial to our work. We will not hesitate to call out political intimidation and fear-driven rhetoric that undermines this trust or that interferes with our ability to deliver the very best care to patients.

Anything less is a rejection of the oath we take as physicians, and of the ethical principles that guide our profession.

More here:
The assault on physicians and science must end - American Medical Association

Study Demonstrates Superior Performance of ThyGeNEXT and ThyraMIR vs. Other Molecular Tests

PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled Multiplatform molecular test performance in indeterminate thyroid nodules was published on-line in the peer-reviewed journal, Diagnostic Cytopathology. This paper represents the culmination of a multi-center, blinded clinical validation study in which gold standard unanimous histopathology consensus diagnosis was utilized. The study results demonstrate that ThyGeNEXT + ThyraMIR combination testing yield the highest positive predictive value (PPV) and similar negative predictive value (NPV) in comparison to other marketed tests for the same indication.

Approximately 25% of thyroid nodule fine needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Ancillary multiplatform testing with ThyGeNEXT and ThyraMIR assists in the accurate risk stratification of these FNAs, ultimately helping to distinguish patients who are more likely to benefit from conservative management from those who are more likely to benefit from surgical intervention.

The published manuscript is the first to report the performance characteristics of combination ThyGeNEXT and ThyraMIR testing in a blinded multicenter study. ThyGeNEXT is the companys most recent next generation sequencing based test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer. The study demonstrates that combination testing with ThyGeNEXT and ThyraMIR has both high sensitivity (95%) and high specificity (90%) for identifying disease. It also highlights the important role that ThyraMIRthe companys proprietary microRNA risk classifiercan play in helping to identify malignancy in nodules where single platform mutation panels commonly detect mutations that by themselves have suboptimal PPV for malignancy.

According to Jack Stover, President and CEO of Interpace, The results of this independent study reported in a well-respected journal reflect the strong clinical performance and overall value of our combined thyroid assays in helping physicians manage their patients with potential thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT is Interpaces most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and most Commercial insurers.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor RelationsEdison Group Joseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com/ mpaul@edisongroup.com

Here is the original post:
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays - GlobeNewswire

Global DNA Sequencing Market Report Covers Market Dynamics, Market Value Chain, And Future Prospective

DNA Sequencing marketis experiencing a growth that the global industry has never-ever seen before. The considerable growth and development are basically due to the current increasing demand and supply on the global platform. The current market dossier provides the necessary details such as the monetary fluctuations, industrial trade, future scopes, and global market status in a smooth-tongued pattern.

The DNA Sequencing market report has some of the major players Abbott Laboratories, ZS Genetics, Inc., Agilent Technologies, Inc., Thermo Fisher Scientific, 454 Life Sciences Corporation (Roche Holding AG), Beckman Coulter (Fullerton, CA), BGI, Illumina, Pacific Biosciences of California, Inc., Siemens AG, F. Hoffmann-La Roche, LI-COR, Inc., Pacific Biosciences of California leading the current global market mentioned. The research report has all the vital details about the past, present, and future aspects of the DNA Sequencing market mentioned with great transparency.

Click here for the free sample copy of the DNA Sequencing Market report

An Overview About the Table of Contents:

Global DNA Sequencing Market Overview Target Audience for the DNA Sequencing Market Economic Impact on the DNA Sequencing Market Global DNA Sequencing Market Forecast Business Competition by Manufacturers Production, Revenue (Value) by Region Production, Revenue (Value), Price Trend by Type Market Analysis by Application Cost Analysis Industrial Chain, Sourcing Strategy, and Downstream Buyers Marketing Strategy Analysis, Distributors/Traders Market Effect Factors Analysis

In the global market, there is always a tough competition going on between the various players so as to top the chart. The current DNA Sequencing market seems to have succeeded in sowing its seed of success and is enjoying the benefits of the reaping taking place on a global platform. The most important aspect provided in the report is the variation in the financial scale that can give the clients a complete idea about the current monetary gain and loss. The geographical segmentation North America (United States, Canada and Mexico), Europe (Germany, UK, France, Italy, Russia and Turkey etc.), Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) gives the readers an entire data about the growth and development taking place across the world. The informative report also presents some data based on the market bifurcations, growth factors, futuristic aspects, industrial policies, and product supply and demand for a better piece of understanding.

Read Detailed Index of full Research Study at::https://www.marketdataanalytics.biz/global-dna-sequencing-market-report-2020-by-key-players-71362.html

Key Insights encompassed in the DNA Sequencing market report

Latest technological advancement in the DNA Sequencing market Studying pricing analysis and market strategies trailed by the market players to enhance global DNA Sequencing market growth Regional development status off the DNA Sequencing market and the impact of COVID-19 in different regions Detailing of the supply-demand chain, market valuation, drivers, and more

One of the vital data mentioned in the report includes that of the overall market segmentation based on the product type, applications, end-users, and various other subtypes. The market segmentation {Semiconductor Sequencing, Pyrosequencing, Sequencing by Synthesis, Single-Molecule Real-Time Sequencing (SMRT), Sequencing by Ligation (SBL), Others}; {Diagnostic, Drug Discovery, Biomarker Discovery, Personalized Medicine, Others} helps the clients and other readers obtain a crystal-clear context about the DNA Sequencing market. The knowledgeable aspects mentioned in the current scientific report is made available at the tip of the finger with just a click.

Questions answered by the DNA Sequencing market report:

Which are regions witnessing the highest growth during the forecast period? How the surging prices of raw materials will affect the growth of the DNA Sequencing market? Which are major market players? How are the market players intensifying their global presence? If yes, how? What are the key strategies used by the market players to improve their market position post the COVID-19 pandemic?

Enquire Here Get customization & check discount for report@https://www.marketdataanalytics.biz/global-dna-sequencing-market-report-2020-by-key-players-71362.html#inquiry-for-buying

Why Choose Market Data Analytics reports?

Our analysts use latest market research techniques to create the report Market reports are curated using the latest market research and analytical tools Customization of report is possible as per the requirement Our team comprises of expertise and highly trained analysts Quick responsive customer support for domestic and international clients

Read the rest here:
Global DNA Sequencing Market 2020 COVID-19 Updated Analysis By Product (Semiconductor Sequencing, Pyrosequencing, Sequencing by Synthesis,...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community. The program seeks to shine a light upon unsung community heroes who often go unrecognized by traditional awards programs and this year saw nominations from 31 states.

The pace at which oncology care is progressing is both rapid and extraordinary, said Chatrick Paul, Head of US Oncology, AstraZeneca. We know that coming together as a community is essential to advancing cancer care and realizing meaningful change for cancer patients. This could not be more true than now when COVID-19 has disrupted efforts of the healthcare community to screen, test and diagnose cancer patients in a timely manner. We know that together, through this program, we can remove barriers to care, transform health systems and support patients beyond our medicines.

Cancer impacts millions of Americans and is something no one should ever have to experience alone, said Jeremy Abbate, Publisher, Scientific American Custom Media. This years winners and finalists collectively embody the sentiment and purpose of the C2 Awards. We are humbled to share their heartfelt stories of dedication and sacrifice to instill new hope for those across our country facing a cancer diagnosis.

The C2 Awards feature four categories, recognizing the community in the following ways: extending quality care to underserved communities, improving the patient experience, advancing precision medicine and doing something tangible and inspiring for patients. Winners will each receive $50,000 donation to pay forward to a non-profit organization serving the cancer community.

The 2020 Cancer Community Awards Recipients

The C2 Catalyst for Change award celebrates those who significantly improve access to cancer care for underserved populations.

The C2 Catalyst for Care award recognizes those who enhance the experience of care for patients during their cancer treatment.

The C2 Catalyst for Precision Medicine award honors those who improve personalized treatment for cancer patients.

The Presidents Award, selected by AstraZeneca, honors those who make a tangible and inspiring difference for patients and their loved ones.

Nominations were evaluated by an esteemed panel of multidisciplinary community leaders, including Edward Abrahams, PhD, President, Personalized Medicine Coalition; Meghan Gutierrez, CEO, Lymphoma Research Foundation; Erin McAllister, formerly at BioCentury; Audra Moran, President & CEO, Ovarian Cancer Research Alliance; Dr Barbara Gitlitz, MD, Medical Oncologist, Keck School of Medicine of USC; Dr Geoffrey Oxnard, MD, Thoracic Oncologist, Dana-Farber Cancer Institute; Dr Keith Winfrey, MD, MPH, Chief Medical Officer, New Orleans East Louisiana Community Health Center; and Leah Fine, Director, Centers of Excellence Program, GO2 Foundation for Lung Cancer.

More details on finalists and winners can be found here.

About YOUR Cancer

The C2 Awards are part of the YOUR Cancer Program, a broader initiative launched by AstraZeneca to spotlight those at the forefront of cancer research and patient support who are contributing toward eliminating cancer as a cause of death. YOUR CANCER aims to convene, engage, and highlight the full breadth of the oncology community, utilizing four pillars: a digital partnership hub profiling community resources and perspectives, an awards program recognizing the unsung heroes of oncology, state-level roundtables with local policymakers and advocates, and media and speaking engagements profiling community oncology leaders.

About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients lives and the Companys future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance Oncology as a growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy, as illustrated by our investment in Acerta Pharma in hematology.

By harnessing the power of four scientific platforms Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

About Scientific American Custom Media

Scientific American's award-winning Custom Media team (SACM) develops targeted, strategic content programs in partnership with corporations, governments, and academic institutions. SACM operates as a division separate from the magazines Board of Editors to create highly engaging, one-of-a-kind media programs for thought-leading audiences. From mini-documentaries or custom events to standalone magazines and native content series, SACM offers its partners opportunities to build compelling and distinct narratives that convey their brand values and unique stories.

See more here:
AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) Awards - Business Wire

The global artificial intelligence (AI) in medicine market was valued at $719 million in 2017 and is estimated to reach $18,119 million at a CAGR of 49.6% from 2018 to 2025. AI is an intelligent system that applies various human intelligence-based functions such as reasoning, learning, and problem-solving skills. AI technology uses software and different algorithms in the field of pharmaceuticals to support the decision-making processes for existing drugs and repurposing drugs to treat other conditions, along with accelerating the clinical trials process by finding the right patients from several data sources.

Major Key Players of the Artificial Intelligence in Medicine Market are:InSilico Medicine, Globavir Biosciences, GNS Healthcare, Flatiron Health, Benevolent AI, Atomwise, Verge Genomics, Cloud Pharmaceuticals, and Recursion Pharmaceuticals.

Get sample copy of Artificial Intelligence in Medicine Market at:http://bit.ly/38ISZeC

Shortage of skilled healthcare professionals and increase in the processing power of AI systems that is projected to help improve the efficiency of drug discovery and management of clinical trials majorly drive the growth of the global artificial intelligence in medicine market. Furthermore, the growth in importance of precision medicine and rise in funding of the R&D activities for the use of AI technology in the field of medicine are expected to fuel the market growth. However, limited acceptance from healthcare professionals and limitations of AI decision-making can impede the market growth. Untapped market opportunities available in developing regions such as India and China help to open new avenues for the growth of the artificial intelligence in medicine market in future.

The global artificial intelligence in medicine market is segmented based on product type, technology, application, and region. Based on product type, the market is segmented into hardware, software, and service. Based on technology, the market is classified into deep learning, querying method, natural language processing, and context aware processing. Based on application, the market is categorized into drug discovery & repurposing, clinical research trial, personalized medicine, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major Types of Artificial Intelligence in Medicine Market covered are:Deep Learning, Querying MethodNatural Language ProcessingContext Aware Processing

Major Applications of Artificial Intelligence in Medicine Market covered are:Drug Discovery & RepurposingClinical Research TrialPersonalized Medicine, and Others

Research objectives:-

To study and analyze the global Artificial Intelligence in Medicine consumption (value & volume) by key regions/countries, product type and application, history data. To understand the structure of the Artificial Intelligence in Medicine market by identifying its various sub-segments. Focuses on the key global Artificial Intelligence in Medicine manufacturers, to define, describe and analyze the sales volume, value, market share, market competitive landscape, SWOT analysis, and development plans in the next few years. To analyze the Artificial Intelligence in Medicine with respect to individual growth trends, future prospects, and their contribution to the total market. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Go For Interesting Discount Here:http://bit.ly/2GpPkpU

Table of Content

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Artificial Intelligence in Medicine Market Size2.2 Artificial Intelligence in Medicine Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Artificial Intelligence in Medicine Market Size by Manufacturers3.2 Artificial Intelligence in Medicine Key Players Head office and Area Served3.3 Key Players Artificial Intelligence in Medicine Product/Solution/Service3.4 Date of Enter into Artificial Intelligence in Medicine Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Artificial Intelligence in Medicine Sales by Product4.2 Global Artificial Intelligence in Medicine Revenue by Product4.3 Artificial Intelligence in Medicine Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Artificial Intelligence in Medicine Breakdown Data by End User

Have any query? Inquiry about report at:http://bit.ly/2NX7xQ3

In the end, Artificial Intelligence in Medicine industry report specifics the major regions, market scenarios with the product price, volume, supply, revenue, production, and market growth rate, demand, forecast and so on. This report also presents SWOT analysis, investment feasibility analysis, and investment return analysis.

About Us-

Market Growth Insight 100% Subsidiary of Exltech Solutions India, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 30000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends.

Contact Us-Email:[emailprotected]Phone: + 91 8956767535Website:https://www.marketgrowthinsight.com

View original post here:
Artificial Intelligence in Medicine Market Advanced Technology and New Innovations by 2025 InSilico Medicine, Globavir Biosciences - PRnews Leader

OAKLAND, Calif.--(BUSINESS WIRE)--In a step toward the full realization of genomic medicine, Fabric Genomics, a leader in AI-based genomic analysis and interpretation, has announced a co-marketing agreement that will provide translational researchers around the world with integrated sample prep to reporting workflows. Combining Roches newly released KAPA HyperExome Probes (RUO) with the Fabric Enterprise bioinformatics and analysis platform will make genetic research faster, less costly and more accurate by providing an end-to-end solution from sample prep through analysis.

Fabric Genomics pioneered AI-driven genomic interpretation, and its Fabric Enterprise software platform for genomic data analysis and reporting is in use by clinical research laboratories, healthcare institutions and country sequencing programs around the world, including Rady Childrens Institute for Genomic Medicine, LabCorp and Genomics England. Last week Fabric Genomics released Fabric GEM, a novel algorithm that quickly identifies the likely genetic cause of rare diseases; the new technology is fully integrated within the Fabric Enterprise platform.

Roches exome sequencing workflow includes the KAPA HyperPrep and HyperPlus library preparation kits and exome probes, which allow users to quickly prepare samples for sequencing while delivering high on-target rates and 98% sensitivity for SNP detection.

In addition to improving turnaround times for genomic sequencing, the combination of these technologies will allow laboratories to increase automation and lower operational costs with improved scalability. Clinical research labs that are expanding assay menus will benefit from reduced costs of development and faster validation.

Clinical research labs have a need to take a collected sample from library prep quickly, all the way through to analysis, and our agreement with Roche demonstrates our commitment to supporting these critical workflows, said Martin Reese, PhD, co-founder and CEO of Fabric Genomics. Using our Fabric Enterprise analysis platform with Roche KAPA HyperExome Probes ensures high coverage of disease-causing genes, which is of the utmost importance in accelerating the identification of rare variants. Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based diagnostics in routine care. With widespread adoption of sequencing technology innovation, we can further our shared goal of improving personalized care.

KAPA products are for research use only (RUO). Not for use in diagnostic procedures.

About Fabric Genomics

Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics. Fabric Genomics is making genomics-driven precision medicine a reality. The company also provides clinical decision-support software that enables clinical labs, hospital systems and country sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabrics end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology.

To learn more, visit https://fabricgenomics.com/roche/ and follow us on Twitter and LinkedIn.

More:
Fabric Genomics to Co-market Comprehensive Sample-to-Genomic Analysis Sequencing Solutions for Hereditary Genetics - Business Wire

2020 has been a historical year from a variety of perspectives, and the stock market is no exception.

The year started off with a strong rally in many high-growth tech stocks, and expectations that global growth was starting to pick up after decelerating since 2018 due to the trade war.

As a result, the S&P 500 was trending higher, making new, all-time highs. However, this pretty picture was wrecked by the coronavirus which caused a 35% crash in stock prices in a little more than a month.

In turn, the Federal Reserve unleashed massive amounts of stimulus to support financial markets by cutting interest rates to zero and starting a bunch of programs to inject liquidity into various markets including corporate bonds. It doubled-down on its dovish stance by stating that interest rates will remain at zero until 2022 and adjusting its inflation framework to make clear to investors that interest rates wont increase until inflation meaningfully climbs above 2%. Previously, the Fed would begin to tighten in anticipation of interest rates hitting 2%.

There was similar aggression on the fiscal front. Due to the economic effects of the shutdown, Republicans and Democrats came together to pass a wide array of bills to boost unemployment checks, provide payroll support to businesses, and investments in health research. In total, this years deficit is expected to be $3.1 trillion due to a combination of lower tax revenue and increased expenditures.

However, this has undoubtedly had positive impacts on the economy as measures like consumer spending and housing have bounced back to levels higher than 2019. Other parts of the economy remain off levels from a year-ago but continue to show improvement on a month to month basis.

These factors also led to a V-shaped rebound in stock prices with the S&P 500 making new highs in August. Over the last two months, the markets momentum has stalled, and weve traded in a sideways range between 3,200 and 3,500.

Most likely, this is a healthy consolidation for the market. Overbought conditions are being relieved to set up the market for its next move higher. For investors who want to take advantage of this bull market and the recent dip, they should consider adding three ETFs with promising prospects into 2021: ARK Genomic Revolution Multi-Sector ETF (ARKG), Invesco Dynamic Leisure and Entertainment ETF (PEJ), and the Materials Select Sector SPDR ETF (XLB).

Reasons to Expect a Q4 Rally

All of these ETFs offer an intriguing upside. However, another important point is the overall trend in the general market, and investors should expect that stock prices will trend higher in the fourth quarter and through 2021. The best way to track the general market is through the SPDR S&P 500 ETF Trust (SPY).

The main factor is we had a major capitulation event in March 2020. Due to this and the economic uncertainty, there is a massive amount of money on the sidelines, specifically institutional funds. As this money is deployed, it will drive the market higher.

Weve seen previous major capitulatory events March 2009, May 2012, and February 2016 from those lows, prices kept moving higher and were strong in the following year. Its also not a coincidence that the Fed was also aggressively dovish during those periods like it is now.

In addition to the Fed, fiscal stimulus is also likely to be deployed if the economy starts to show signs of weakness. This also another reason to be supportive of the buy the dip trade. The polls also show a 65% chance that Joe Biden wins the Presidency and a 60% chance that Democrats win the Senate. This would increase the size and chances of stimulus being passed.

Another major catalyst for stock prices is that fund managers are underinvested and underexposed. The average fund is down around 7%, while the S&P 500 is up 5% YTD. The average fund manager is also underinvested in terms of stock exposure. Fund managers are assessed by how they perform relative to their benchmarks.

If they end the year underperforming by a significant margin, there is the chance that they will lose capital or their jobs. So, if stock prices keep creeping higher, many fund managers would be forced to buy, pushing shares up even more.

Of course, this dynamic is happening during a pretty bullish time seasonally. As the chart below shows, Q4 during a Presidential election year tends to be bullish. And, the gains could be particularly outsized this year if fund managers are piling in.

(source: LPL Financial)

ARK Genomic Revolution Multi-Sector ETF (ARKG)

While the markets are expected to move higher into Q4, investors should look at growth areas. Among these, biotechs are intriguing. The sector is benefiting from increased investment due to COVID-19, however, long-term fundamentals are solid due to the aging population and constant need for new treatments and therapies.

Additionally, the biotech sector has traded sideways for the last 5 years, while earnings have kept increasing, meaning that valuations are attractive. Within biotech, the most exciting area is genomics. ARKG is an ETF that gives diversified exposure to this group.

Genomics is in the early stages of transforming medicine. Currently, they are used more in diagnostics but scientists anticipate that they could be used in the future to repair cells at the cellular level and would lead to a future of personalized medicine. ARKG is a diversified way to take advantage of new development in medicine.

ARKG is rated a Buy according to the POWR Ratings. It has an A for Trade Grade and Industry Rank with a B for Buy & Hold Grade. Amongst Health & Biotech ETFs, its ranked #4 out of 38.

Invesco Dynamic Leisure and Entertainment ETF (PEJ)

PEJ is composed of a basket of restaurants, entertainment, and retail stocks. Whats interesting is that in recent months its shown signs of outperformance after underperforming for the duration of the rally. This is despite negative headlines with case counts rising and failure to reach agreement on a second stimulus deal.

The best trades come when sentiment is the most depressed. Currently, no sector is hated more than casinos, restaurants, and travel stocks. While many stocks made new highs since the March bottom, this group has massively underperformed.

Negative sentiment has increased in recent weeks as its clear that we are on the verge of a second wave: However, the data is also clear that deaths are not increasing as treatment has significantly improved. Many also believe that the prevalence of mask-wearing and social distancing means that viral loads are lower.

Additionally, TSA travel data, restaurant booking figures, and recent reports from casinos show that normalization is continuing. The world is going to return to normal at some point whether its in 2021 or 2022. Already, we are seeing a movement towards normalization despite case counts rising and no vaccine.

Materials Select Sector SPDR ETF (XLB)

Another interesting sector is materials stocks. For one, they have been in a downtrend since 2018, so they are interesting from a contrarian, value perspective. Additionally, one tailwind for the sector is that we are on the verge of a restocking cycle as inventories will need to be replenished as the world returns to normal.

Further, every government is using fiscal stimulus to combat the economic slowdown due to the coronavirus. This means more infrastructure projects. Already, we are seeing bullish price action in cyclical commodities like copper, iron ore, and lumber. All of these indicate that building activity and manufacturing will do well.

On a technical basis, XLB is outperforming on a shorter timeframe. If the virus gets worse to the extent that it will slow economic activity, then the sector will benefit from additional fiscal and monetary stimulus. If the recovery continues, then XLB will also do well due to the increased demand for materials.

According to the POWR Ratings, XLB is a Strong Buy, and it has an A for Trade Grade and Buy & Hold Grade. Among Industrial ETFs, its ranked #1 out of 33.

Want More Great Investing Ideas?

Top 11 Picks for Todays Market

Dangerous Outlook for Stocks Into Election

5 WINNING Stocks Chart Patterns

SPY shares fell $4.33 (-1.25%) in premarket trading Monday. Year-to-date, SPY has gained 8.97%, versus a % rise in the benchmark S&P 500 index during the same period.

Jaimini Desai has been a financial writer and reporter for nearly a decade. His goal is to help readers identify risks and opportunities in the markets. As a reporter, he covered the bond market, earnings, and economic data, publishing multiple times a day to readers all over the world. Learn more about Jaiminis background, along with links to his most recent articles. More...

Follow this link:
SPY: 3 ETFs That Could SOAR Into 2021 - StockNews.com

The research report on Age Related Macular Degeneration Biologic Drug Market gives thorough insights regarding various key trends that shape the industry expansion with regards to regional perspective and competitive spectrum. Furthermore, the document mentions the challenges and potential restrains along with latent opportunities which may positively impact the market outlook in existing and untapped business spaces. Moreover, it presents the case studies, including the ones related to COVID-19 pandemic, to convey better understanding of the industry to all the interested parties.

The recent market trend of increasingly using Age Related Macular Degeneration Biologic Drug for understanding the development of a disease extensively fuel the growth of this market in the coming years. Another trend that will aid the growth of the global Age Related Macular Degeneration Biologic Drug market is the escalating demand for personalized medicine. Extensive investments are being made by various organizations, pharmaceutical companies, and governments for the research and development of drugs, and this is another trend that is benefiting the growth of the global Age Related Macular Degeneration Biologic Drug market. This is because Age Related Macular Degeneration Biologic Drug techniques enable researchers to compare Age Related Macular Degeneration Biologic Drug changes between disease samples and normal samples. Public health can thus be analyzed as the changes in Age Related Macular Degeneration Biologic Drug are influenced by internal biological system and environment directly.

Request a sample of this premium research: https://www.bigmarketresearch.com/request-sample/3927283?utm_source=Nilesh-TKC

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include: Regeneron, Valeant, Novartis, Genentech, Allergan, Eli Lilly, Alimera Sciences, Merck, Acucela, Bayer, Ophthotech Corporation.

Age Related Macular Degeneration Biologic Drug Market Segmentation:

In market segmentation by types of Age Related Macular Degeneration Biologic Drug, the report covers-

RanibizumabBevacizumabAflibercept

In market segmentation by applications of the Age Related Macular Degeneration Biologic Drug, the report covers the following uses-

Outpatient Surgery CenterEye ClinicHospital

Regional Analysis for Age Related Macular Degeneration Biologic Drug Market-:

1) North America- (United States, Canada)

2) Europe- (Germany, France, UK, Italy, Russia, Spain, Netherlands, Switzerland, Belgium)

3) Asia Pacific- (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Vietnam)

4) Middle East & Africa- (Turkey, Saudi Arabia, United Arab Emirates, South Africa, Israel, Egypt, Nigeria)

5) Latin America- (Brazil, Mexico, Argentina, Colombia, Chile, Peru)

The report provides insights on the following pointers :

Market Penetration: Comprehensive information on the product portfolios of the top players in the Supply Chain Analytics market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Supply Chain Analytics market

NOTE: Our analysis involves the study of the market taking into consideration the impact of the COVID-19 pandemic. Please get in touch with us to get your hands on an exhaustive coverage of the impact of the current situation on the market. Our expert team of analysts will provide as per report customized to your requirement.

Request a discount on standard prices of this premium research: https://www.bigmarketresearch.com/request-for-discount/3927283?utm_source=Nilesh-TKC

Table of Content

Chapter 1 Age Related Macular Degeneration Biologic Drug Introduction and Market Overview

Chapter 2 Executive Summary

Chapter 3 Industry Chain Analysis

Chapter 4 Global Age Related Macular Degeneration Biologic Drug Market, by Type

Chapter 5 Age Related Macular Degeneration Biologic Drug Market, by Application

Chapter 6 Global Age Related Macular Degeneration Biologic Drug Market Analysis by Regions

Chapter 7 North America Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 8 Europe Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 9 Asia Pacific Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 10 Middle East and Africa Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 11 South America Age Related Macular Degeneration Biologic Drug Market Analysis by Countries

Chapter 12 Competitive Landscape

Chapter 13 Industry Outlook

Chapter 14 Global Age Related Macular Degeneration Biologic Drug Market Forecast

Chapter 15 New Project Feasibility Analysis

Trending Market Research Reports :

COVID-19 Outbreak-Global Large Volume Wearable Injectors Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020: https://zenitnews.com/news/137473/large-volume-wearable-injectors-market-expert-guide-to-boost-the-industry-in-global-market-share/

COVID-19 Outbreak-Global Malaria Diagnostics Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020: https://eurowire.co/coronavirus/501431/malaria-diagnostics-industry-global-market-trend-share-profit-growth-and-key-manufacturers-analysis-report/

2020-2025 Global and Regional Web Server Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report: https://rejerusalem.com/190476/web-server-market-size-share-trend-analysis-growth-factor-and-analysis-by-its-key-vendors-2025/

About Us:

Big Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Mr. Abhishek Paliwal

Big Market Research

5933 NE Win Sivers Drive, #205, Portland,

OR 97220 United States

Direct: +1-971-202-1575

Toll Free: +1-800-910-6452

E-mail: [emailprotected]

Visit link:
Most recent development report on Age Related Macular Degeneration Biologic Drug Market to Witness Exponential Rise in Revenue Share during the...

HOLMDEL, N.J., Oct. 20, 2020 /PRNewswire/ -- The 5th Annual Companion Diagnostics Forum will take place Tuesday and Wednesday, October 27-28, 2020. Register at http://companiondiagnosticsforum.com.

"The online Companion Diagnostics Forum is focused on the need for Companion Diagnostics to grow and keep pace with novel developments in Pharma," said Event Chair Oscar Puig from Eli Lilly, adding, "We are providing access to key people in this important field that are working every angle to ensure patients get the personalized medicine they require."

Keynote speaker Steve Anderson, CSO from Covance, explained that"Companion diagnostics are a critical component for delivering on the promise of precision medicine. This conference brings together industry leaders to discuss and review innovations and emerging applications in companion diagnostics."

Some of the therapeutic areas that will be covered are Oncology, ALS and trauma-related disorders. Education, regulations and adoption in clinical applications will be discussed at this year's forum. Speakers will addresshow these various areas are combining to bring better healthcare to patients.

Ronnye Schreiber, CEO, PlanetConnect and event organizer, said, "We are pleased that we can offer this custom virtual environment to ensure that the Forum could move forward even though we cannot meet in-person."

See a complete agenda and register online at http://www.companiondiagnosticsforum.com.

About PlanetConnect The Companion Diagnostics Forum is produced by PlanetConnect, a certified woman-owned conference producer and event production company with more than 25 years experience running scientific symposia for pharmaceutical, research, IT and manufacturing organizations. With decades of experience providing cost-effective, creative solutions, PlanetConnect enables companies to focus on making meaningful connectionsnot just meetings.

Contacts:Event Chair: Oscar Puig, Translational Medicine, Oncology Late Stage Development, Eli Lilly [emailprotected] Event Manager: Ronnye Schreiber, CEO, PlanetConnect, [emailprotected]

SOURCE PlanetConnect

http://www.planetconnect.com

See the rest here:
The 5th Annual Companion Diagnostics Forum on Oct 27-28 gathers scientists, clinicians, regulators and industry professionals for two days of...

Data from a 5-year open-label treatment period on the safety profile of erenumab (Aimovig) showed the treatment helped patients with episodic migraine (EM) achieve a sustained reduction in the number of monthly migraine days (MMD) and the number of days in which therapies were needed for acute migraines.

The set of data we have now obtained is very, very important from the clinical point of view,said Messoud Ashina, MD, PhD, professor of neurology in the Faculty of Health and Medical Sciences at theUniversity of Copenhagen and lead investigator of the study.

Erenumab, which wasapprovedby the FDA in 2018, is a calcitonin gene-related peptide (CGRP) inhibitor administered via self-injection once a month. The treatment blocks the CGRP receptor, which is believed to play a crucial role in migraine. Erenumab can be injected as a 70- or 140-mg dose in adults with migraine. Results from the phase 2 study were initially published during the Migraine Trust Virtual Symposium.

In an interview with The American Journal of Managed Care (AJMC), Ashina reviewed the findings and discussed potential next steps for the treatment.

The sustained efficacy of erenumab is integral, as many migraineurs experience a wearing off of treatment effects after 3 or 4 months on a single preventive therapy, Ashina explained. Furthermore, the study found that erenumabs safety profile was nearly identical to that observed during the double-blind period, and no additional adverse reactions were reported. The most common adverse events included nasopharyngitis and upper respiratory tract infections.

Although roughly 70% of the 216 patients enrolled in open-label phase of the study reported long-term efficacy, researchers do not yet know what accounts for the heterogeneity in terms of response. So far, we havent found any predictors for efficacy, and we need more research and more new studies to explain why this group of patients does not respond to monoclonal antibodies, Ashina said.

Currently, the Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine (OASIS EM) trial is underway. When it comes to the treatments effects in pediatric populations, Ashina expects to see similar long-term results. This is one of the areas with a huge unmet need for new treatments, he said. Medications currently available for children can have side effects and adverse events, making some specialists hesitant to prescribe preventive treatments to younger populations.

Based on the safety and tolerability that we see in an adult population [with erenumab], we would expect to also see positive results in children, as this population also has a high frequency of episodic migraine, Ashina said. But lets see, because we havent seen data yet.

OASIS EM is estimated to be completed in August 2025.

In addition to studies on erenumabs efficacy in children, Ashina noted that future studies ought to be conducted on predicting the treatments efficacy in patients. If predictive markers of efficacy are found, this will also pave the way for personalized medicine in the future.

The second issue is with erenumab and also other monoclonal antibodies is about safety and tolerability in patients with different comorbidities, Ashina explained. As most clinical trials do not include patients with serious comorbidities, real-world data will be essential to understand the effects of erenumab on these patients.

Registry studies can also be used to track any effects that monoclonal antibody treatments may have on pregnant women. Erenumab is currently contraindicated during pregnancy, but you can imagine that when you have a drug with a long half-life, and if you get pregnant, it might theoretically affect the baby, Ashina said.

Excerpt from:
Dr Messoud Ashina Talks Through the 5-Year Safety and Efficacy Data on Erenumab - AJMC.com Managed Markets Network

CHICAGO, Oct. 20, 2020 /PRNewswire/ -- According to the new market research report "Research Antibodies and Reagents Marketby Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blotting, Flow Cytometry), Application (Proteomics, Drug Development), End User - COVID-19 Impact - Global Forecast to 2025",published by MarketsandMarkets, the global market size is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period.

The growth is due to evolution of market owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global market is expected to witness significant growth in the coming years.

Browse in-depth TOC on "Research Antibodies and Reagents Market"

220 Tables 45 Figures 278 Pages

Download PDF Brochure:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793

The COVID-19 outbreak has boosted research activity due to efforts to understand the dynamics of the infection. We estimate that the major share of research antibody and reagent manufacturing, along with personalized medicine, will grow at a stable pace in the next five years. Due to the increase in research activity, both the availability of funding for research and the demand & manufacturing of reagents and antibodies are expected to grow. As companies after pandemic have scaled up their operations for testing and tracking the infection of COVID-19. This has given a chance for growth in profits for companies operating in the NGS and PCR markets. The growth in revenue is 57%, as COVID-19 testing has increased with the use of the latest technology of genetic and molecular testing. The shift in demand for research for COVID-19, neurobiology, and oncology has created a huge scope for testing solutions, such as western blotting, flow cytometry, ELISA, and drugs for researchers and laboratories.

The antibodies segment is expected to grow at the highest CAGR during the forecast period

Based on product, the research antibodies market is segmented into reagents and antibodies. The antibodies segment is expected to grow at highest CAGR in forecast period. This is due to the research-use antibodies offer high specificity and selectivity and are used ubiquitously in biochemical and medical research for protein-target identification, regulatory characterization, and discovery.

The primary antibodies segment is accounts for the largest share of the research reagents market

Based type, the research reagents market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment held the largest share of the global research antibodies market in 2019. This segment is witnessing a strong growth due to the use of these antibodies in numerous types of assay formats. Their accuracy in biomarker detection and their high specificity and sensitivity are also driving their adoption

The media & sera reagent is expected to account for the largest share of the market, by type, in 2019

Based type, the research antibodies and reagents market is segmented into media &sera, stains & dyes, fixatives, buffers, solvents, enzymes, probes and other reagents. The media & sera reagent segment held the largest share of the global research antibodies market in 2019. The large share of this segment is primarily attributed to the use of these components in all types of assays, cell cultures, and techniques.

The western blotting segment is expected to account for the largest share of the market, by technology, in 2019

Based on technology, the research antibodies market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. Western blotting segment is expected to grow at highest CAGR in forecast periods (2020-2025). This is due to the high adoption of this technique in proteomic and genomic research. The results achieved are easy to interpret, unique, and unambiguous, making it suited for evaluating levels of protein expression in cells, monitoring fractions during protein purification, and comparing the expression of a target protein from various tissues.

The pharmaceutical & biotechnology segment is expected to grow at the highest CAGR during the forecast period

Based on end user, the research reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. The growth of this segment is due to antibodies provide a gold standard for the detection of a biomolecule or a pathway and are even capable of detecting specific changes in potential drug targets. Additionally, highly specific reagents are used to measure pharmacokinetic parameters in the preclinical and clinical development of biological drugs. The increasing demand for personalized medicine and government initiatives in this sector are the key market drivers for this segment.

Get 10% Customization on this Research Report:

https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=94212793

The APAC market is expected to grow at the highest CAGR during the forecast period

The Asia Pacific research reagents market is expected to grow at the highest CAGR from 2020 to 2025.The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also, high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.

The prominent market players are Thermo Fisher Scientific (US), Merck Group (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports:

https://www.marketsandmarkets.com/RequestBundleReport.asp?id=94212793

Browse Related Reports:

Flow Cytometry Market by Technology (Cell-based, Bead-based), Product (Analyzer, Sorter, Reagents, Consumables, Software), End user (Academia, Research Labs, Hospitals, Clinical Laboratories, Pharma-Biotech Cos), Application - Global Forecasts to 2025

https://www.marketsandmarkets.com/Market-Reports/flow-cytometry-market-65374584.html

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023

https://www.marketsandmarkets.com/Market-Reports/custom-antibody-market-164328301.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected]Research Insight: https://www.marketsandmarkets.com/ResearchInsight/research-antibodies-reagents-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/research-antibodies-reagents.asp

SOURCE MarketsandMarkets

Read more from the original source:
Research Antibodies and Reagents Market worth $14.1 Billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. These are the top 10 companies in Europe that are working to make AI drug discovery a reality.

Drug development is a slow and increasingly expensive process. Artificial intelligence (AI) has the potential to make the drug development process quicker, cheaper and more efficient. This technology can make scanning vast libraries of chemical compounds that might be able to treat a certain disease easier, can speed up the analysis of biomedical information from the literature, and can help companies recruit the most suitable patients for clinical trials. AI can also streamline the design of better drugs and incorporate new data, such as genomic analysis, to help personalized medicine become a reality.

There are now an increasing number of companies that are using AI to improve drug discovery and development in a variety of different ways. We enlisted the help of experts in the industry to select the top European companies in this area. As ever, these are in no particular order.

Location: Oxford, UKFounded: 2012

Exscientia was one of the first companies to apply AI technology to drug discovery. Its focus is to quickly identify and optimize drug candidates that are more likely to succeed in clinical trials than those selected by conventional means.

The companys first AI-designed drug candidate, to treat obsessive-compulsive disorder, began human testing in a phase I trial earlier this year. It took Exscientia 12 months to bring the candidate to clinical trials rather than the average time of around five years. More recently, the company announced it was working with US partners to apply its technology to searching for drug candidates to treat Covid-19.

The Oxford-based company has deals with Bayer, BMS, Sanofi, GSK, and Celgene to co-develop new drugs for a variety of diseases and conditions. Exscientia also closed an impressive 54M Series C round at the end of April, in the midst of the Covid-19 pandemic.

Location: Cambridge, UKFounded: 2014

Healx uses AI to analyze extensive medical research data with the goal of repurposing and finding new combinations of existing drugs to treat rare diseases such as fragile X syndrome, Angelman syndrome and muscular dystrophy.

The company raised a 50.8M Series B round in October 2019. Shortly after, Healx announced it was committing 17M to run its Rare Treatment Accelerator program, allowing patient groups a chance to work with the company to find new treatments for rare diseases.

The companys most advanced program, a drug repurposed for fragile X syndrome, took less than two years to reach clinical trials instead of the normal five-to-seven years this process usually takes. Like many others, Healx is using its technology to search for treatments for Covid-19.

Location: London, UKFounded: 2013

BenevolentAI has developed an AI platform that can identify new drug target candidates for any therapeutic area. The company has its own pharmaceutical team to investigate potential leads and develop their own products. The company began life as Stratified Medicine before changing its name in 2016.

BenevolentAI is working in a variety of disease areas including Alzheimers and ALS. While the company is working on its own drug candidates, it also has various partnerships including with the big pharma companies AstraZeneca and Novartis. BenevolentAI recently hit the news when it discovered a potential treatment for Covid-19, the existing rheumatoid arthritis drug baricitinib, which has shown to improve and speed up the recovery of hospitalized patients with Covid-19.

The company technically reached unicorn status in 2018 when it achieved a valuation of 1.7B after a big fundraising. However, the companys valuation suffered significantly when Neil Woodford, who had been a major investor, was forced to wind up his fund in 2019, though the valuation has since improved again.

Location: Eschborn, GermanyFounded: 2011

Unlike other companies in the field, Innoplexus doesnt develop its own pharmaceuticals, Instead, the firm gives pharma companies, biotechs, contract research organizations and life sciences professionals access to its data platform to help them design better drugs and improve decision making throughout the drug development process.

The company uses AI and blockchain to search published papers, online data from presentations, symposiums and conferences, clinical trial data, and publicly available hospital data as well as unpublished datasets.

Last spring, Innoplexus closed a Series C round worth an undisclosed amount in the double-digit millions. In March, The company released an analysis of hundreds of clinical studies that suggested a treatment for Covid-19 consisting of hydroxychloroquine combined with a variety of other drugs, including Gileads antiviral remdesivir.

Location: Copenhagen, DenmarkFounded: 2008

Evaxion has a focus on infectious diseases and oncology. The company has developed two AI platforms that can be used to create immunotherapies by selecting the antigens that are most likely to produce strong immune responses against infections or cancer.

One of the platforms is used for the development of personalized cancer immunotherapies. In April 2019, the company dosed its first patient with its lead candidate, a therapeutic vaccine targeting solid tumors. The other platform can identify vaccine antigens that trigger protective responses against pathogenic bacteria in less than a day.

At the end of last year the company raised 16M. As with most of the other companies in this space, Evaxion has launched its own Covid-19 effort an AI platform designed to enable a faster response to emerging viral pandemics by identifying potential vaccines and taking them to clinical trials within just 13 weeks.

Location: Frankfurt am Main, GermanyFounded: 2016

Genome Biologics has a focus on RNA interference therapies for cardiovascular and cardiometabolic diseases. The company uses an AI platform to assist in identifying suitable drug targets and also allows 2D and 3D investigation of RNAi disease targets in a variety of animal models.

Genome Biologics was developed with support from the Johnson & Johnson Innovation Labs Incubator in Beerse, Belgium, where the company has an office. The company is still young, but has raised 2.5M in grant and seed funding to further develop its technology. Its lead candidate treatment is expected to start phase I/II testing in heart failure patients next year.

Genome Biologics recently joined Blue Knight, a collaboration of companies created by Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) in the US, that aims to anticipate potential global health threats and infectious diseases.

Location: Lyon, FranceFounded: 2010

Novadiscovery uses data from preclinical and clinical studies to model a drugs effect on patients and predict whether it will be successful or not at treating a specific disease. The company has worked on a wide range of indications including liver disease, respiratory disease, hepatitis, immuno-oncology, and cardiovascular disease.

Compared to other similar companies, Novadiscovery is able to work with small and large data sets alike. The AI platform is also designed to be transparent and allow users to check if the tool is working correctly.

The company raised 5M in Series A funding earlier this year to develop its technology further and offer it to clients as a cloud-based service where users pay for access.

Location: Dublin, IrelandFounded: 2014

Nuritas uses its AI platform to search and analyze large libraries to find potential drug candidates or nutritional additives. In particular, the company focuses on identifying and developing peptide drugs.

Although it has a strong focus on developing nutritional supplements, Nuritas is also using its platform to develop potential drug candidates. The company is currently investigating a fibrosis target that is implicated in a number of diseases including liver, renal and cardiac disease.

Nuritas has raised 53.9M since it was founded in 2014 and has collaborations with big players such as Nestle, Johnson & Johnson and BASF. The company has also joined the Covid-19 effort and is searching for antiviral peptides that could block the virus causing Covid-19, SARS-CoV-2, from infecting cells or locally reduce lung inflammation without the need for complete immunosuppression.

Location: Budapest, HungaryFounded: 2015

Turbine has a focus on cancer. The company has built a dynamic computational model of human cell biology that uses AI to predict how cancer cells respond to drugs and finds new targets, biomarkers and therapies. By running thousands of simulated experiments, this technology can dramatically speed up drug development.

Turbine is currently focusing on DNA damage repair targets, found in 30% of cancers, particularly in patients resistant to other therapies. The company secured 3M in seed funding at the end of last year and has partnered with German big pharma Bayer to develop new applications for its existing cancer drugs. It also has its own preclinical-stage drug development programs in development.

Location: Tel Aviv, IsraelFounded: 2016

Tel Aviv-based CytoReason is definitely worth a mention on this list. The company has one of the largest libraries of human molecular data in the world. It uses this information to create computational cell models of the human immune system to advance drug development.

For example, an analysis of melanoma biopsies using the companys AI platform identified that patients who responded to the drug nivolumab had higher numbers of adipocyte cells than those who did not. The company has also discovered several potential new targets for this cancer that had not previously been investigated.

CytoReason has not revealed its funding to date, but has high-value partnerships with several big pharma companies including Pfizer, GSK and Roche focusing on drug development in immunology.

Visit link:
Top 10 Companies Combining AI and Drug Discovery in... - Labiotech.eu

TUCSON, Ariz., Oct. 21, 2020 /PRNewswire/ --Registration is now open for the World Cord Blood Day 2020 virtual conference (register free on Eventbrite) featuring world renown cord blood transplant doctors and cellular therapy researchers. To be held on November 17th, the virtual conference will provide an opportunity for healthcare professionals, expectant parents, and students to learn about life-saving cord blood stem cells via a mix of livestream and on-demand sessions. The public is also invited to participate in a wide variety of free educational events being held around the globe by WCBD Official Participants (see listings on http://www.WorldCordBloodDay.org).

Attendees of the virtual conference will learn how cord blood has been used in more than 40,000 stem cell transplants since 1988 to treat over 80 life-threatening diseases including leukemia, sickle cell anemia, thalassemia, and lymphoma. Ground-breaking research will also be presented by scientists who are discovering cord blood's full potential in CAR-NK immunotherapy, the emerging field of regenerative medicine to potentially treat autism, cerebral palsy, Covid-19 related MIS-C and more. Keynote presentations will be made by Dr. Joanne Kurtzberg (Duke Department of Pediatrics, Duke Center for Autism and Brain Development), Dr. Katy Rezvani (MD Anderson Cancer Center), Dr. Jonathan Gutman (University of Colorado), Dr. Leland Metheny (Case Western Reserve University), and Monroe Burgess (Quick Specialized Healthcare Logistics). Dr. Moshe Israeli (Rabin Medical Center) will lead the opening session on HLA matching and cord blood.

In addition, a panel of industry experts will discuss how cord blood has come to the forefront during the Covid-19 pandemic. Increasingly, stem cells transplant doctors are using cord blood units collected well before the pandemic and now available for immediate use. Attendees will also hear from Dr. David Hall and Vanessa Yenson, who both beat cancer thanks to cord blood transplants.

To view the full agenda, please visit: https://www.worldcordbloodday.org/online-medical-conference-agenda-wcbd-2020.html

Organized and hosted by Save the Cord Foundation (501c3 non-profit), this year's event is officially sponsored by Quick Specialized Healthcare Logistics. "We're proud to be a sponsor of World Cord Blood Day for the fourth year in a row. This year is sure to be very informative and exciting, providing the latest information from some of the industry's top doctors and researchers. We're humbled to play a role in the research and development of cord blood derivative therapies by providing logistics supply chain solutions to cord blood, biotech and pharmaceutical companies worldwide," said David Murphy, Executive VP of Quick's Life Science Division.

Inspiring Partners this year include the Cord Blood Association (CBA), Be the Match (NMDP), World Marrow Donor Association (WMDA-Netcord), AABB Center for Cellular Therapy and Foundation for the Accreditation of Cellular Therapy (FACT).

Visit http://www.WorldCordBloodDay.org to learn how you can participate and/or host an event. Join us on social media using the hashtags: #WCBD20 and #WorldCordBloodDay.

About Save the Cord Foundation

Save the Cord Foundation (a 501c3 non-profit) was established to advance cord blood education. The Foundation provides non-commercial information to parents, health professionals and the public regarding methods for saving cord blood, as well as current applications using cord blood and the latest research. Learn more at http://www.SaveTheCordFoundation.org.

About Quick Specialized Healthcare Logistics

Quick is the trusted logistics leader serving the Healthcare and Life Science community for almost 40 years. Quick safely transports human organs and tissue for transplant or research, blood, blood products, cord blood, bone marrow, medical devices, and personalized medicine, 24/7/365. Quick's specially trained experts work with hospitals, laboratories, blood banks and medical processing canters, and utilize the safest routes to ensure integrity, temperature control and chain of custody throughout the transportation process. Learn more at http://www.quickhealthcare.aero.

Media Contact:Charis Ober[emailprotected]520-419-0269

SOURCE Save the Cord Foundation

http://www.SaveTheCordFoundation.org

The rest is here:
World Cord Blood Day 2020 Speakers to Present Revolutionary CAR-NK Cell Therapy, Potential Treatments for Covid-19 Related MIS-C and Advantages of...

Not even a week after Nvidia announced that it would be providing hardware for the first four of the eight planned EuroHPC systems, HPE and AMD are announcing another major EuroHPC design win. Finnish supercomputing center CSC revealed today that its forthcoming LUMI system commissioned under the auspices of EuroHPC will be built by HPE using AMD processor technology. With a target Linpack performance of 375 petaflops, LUMI is the second of three planned pre-exascale machines under EuroHPC to have its hardware detailed. The system also breaks new ground in energy efficiency.

The system

LUMI is based on the HPE Cray EX supercomputer architecture, and will harness next-generation AMD Epyc CPUs and AMD Instinct GPUs. Storage will include 7 PB of accelerated flash-based storage (LUMI-F, utilizing a Cray ClusterStor E1000 storage system); an 80 PB Lustre file system (LUMI-P); and 30 PB of encrypted object storage (LUMI-O). LUMIs primary GPU-driven partition (LUMI-G) will be supplemented by a data analytics partition with 32 TB of memory and additional GPUs (LUMI-D), as well as a CPU partition featuring around 200,000 AMD Epyc CPU cores. LUMI will use HPE Slingshot networking.

LUMIs main partition is expected to deliver over 550 peak petaflops of computing power, just above (current Top500 leader) Fugakus 513.8 peak petaflops. Committed Linpack performance, meanwhile, is 375 petaflops (shy of Fugakus 415.5). This makes LUMI the most powerful of the five planned EuroHPC systems that have been detailed so far: Italys Leonardo system is expected to deliver over 200 peak petaflops; Luxembourgs Meluxina, over 18; the Czech Republics EURO IT4I, 15.2; and Slovenias Vega, 6.8.

Energy efficiency & siting

LUMI will support research from ten countries, comprising a new LUMI consortium: Belgium, the Czech Republic, Denmark, Estonia, Finland, Iceland, Norway, Poland, Sweden and Switzerland. The consortium says that LUMI will enable more precise climate models; advanced AI applications in areas like self-driving vehicle development; large-scale social science analytics; personalized medicine research; and much more. Up to 20 percent of LUMIs capacity will be reserved for European industry and small- and medium-sized enterprises (SMEs).

The system will be installed in a new datacenter at CSCs campus in Kajaani, Finland, where CSC says the system will take up roughly the size of a tennis court. The datacenter is expected to be ready by Q4 2020; the first phase of LUMI, by Q2 2021; and the second phase of LUMI, by Q4 2021. LUMI will use 100 percent renewable energy (thanks to local hydropower) and its waste heat will be used to supply approximately 20 percent of the yearly district heating needs of its host town, resulting in a stated net negative carbon footprint of 13,500 tons of CO2 equivalent per year.

HPE says that LUMI will use approximately 8.5 megawatts, which translates into an extremely efficient 44.1 gigaflops per watt. For context, this is nearly double the efficiency of thecurrent Green500 leader, MN-3, which delivers 21.1 gigaflops per watt. Extrapolating LUMIs numbers out, an exascale system would require just around 22.7 megawatts well within the 40-megawatt limit targeted by the planned U.S. exascale systems (a goal that requires a minimum efficiency of 25 gigaflops per watt), and close to the ambitious 20-megawatt exascale goal set by the U.S. Defense Advanced Research Project Agency (DARPA) in the early 2010s. With HPE supplying those three exascale systems as well, this may be the first real preview of those systems computational efficiency.

Once operational in mid-2021, the LUMI supercomputer will be one of the most competitive and green supercomputers in the world, said Anders Jensen, executive director of EuroHPC. Such [a] leadership-class system will support European researchers, industry and [the] public sector in better understanding and responding to complex challenges and transforming them into innovation opportunities in sectors like health, weather forecasting or urban and rural planning.

LUMIs total cost of ownership through 2026 is expected to be approximately 200 million ($237.1 million), of which 140 million ($165 million) will go toward the supercomputer itself. This cost will be split between the European Commission (100 million), Finland (50 million) and the remaining nine countries in the LUMI consortium (50 million).

The EuroHPC roadmap

LUMI is the second EuroHPC system so far that is being built by HPE (with the other being EURO IT4I). Leonardo, Meluxina and Vega, meanwhile, are all being built by French IT firm Atos. As a U.S. company, HPE appears to have successfully wooed EuroHPC with promises to bring some of its operations across the pond: HPE will be manufacturing liquid-cooled Cray EX supercomputers and Apollo systems in its Kutn Hora factory in the Czech Republic (where EURO IT4I will be based), and the company has also committed to establishing a Center of Excellence in Europe that will provide R&D services and expertise in support of exascale readiness.

Three of the eight planned EuroHPC systems are yet to be detailed: the four-petaflops PetaSC system, hosted by Sofia Tech Park in Bulgaria; the ten-petaflops Deucalion system, hosted by the Minho Advanced Computing Center in Portugal; and the 200-petaflops MareNostrum 5 system, hosted by the Barcelona Supercomputing Center in Spain. By process of elimination, MareNostrum 5 will be the last of the three pre-exascale systems to be fully announced. For the third machine, the tendering process is in its very final phase now, Jensen said, so there will be announcements on that in the coming weeks.

LUMI is the latest in a series of wins for HPEs Cray EX systems, which will serve as the basis for the three planned U.S. exascale systems (Aurora, El Capitan and Frontier) and Australias most powerful supercomputer (just announced this week). Conspicuously absent, however, are mentions of the European Processor Initiative (EPI) and its planned first-generation Rhea CPUs, ostensibly slated for 2021. Jensen maintains that the EPI continues to factor into the future of EuroHPC.

The ambition is that when we get to the exascale systems which is what we will be discussing in the coming years that EPI will deliver a processor that we can base at least one of the upcoming exascale systems on, he said.

Header image: concept art of the LUMI supercomputer. Image courtesy of CSC.

Read this article:
HPE, AMD and EuroHPC Partner for Massive LUMI Supercomputer - HPCwire

PALM BEACH, Fla., Oct. 21, 2020 /PRNewswire/ --Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies. Adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options areresulting in discovery of new therapeutic options for cancer treatment. A recent industry reportfrom MarketsAndMarkets projected that the global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. The growth of this market is majorly attributed to the rising prevalence of target diseases, increasing demand for monoclonal antibodies and biosimilars, increasing adoption of immunotherapy drugs over conventional treatments, and a favorable approval scenario. However, timeline issues, side-effects, and manufacturing complexities and a high attrition rate in the product development cycle are expected to challenge market growth. Active biotech and pharma companies in the markets this week include Actinium Pharmaceuticals, Inc. (NYSE: ATNM), AstraZeneca PLC (NASDAQ: AZN), Bristol Myers Squibb (NYSE: BMY), Northwest Biotherapeutics(OTCQB: NWBO), Merck (NYSE: MRK).

The report said that: "Based on type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapies. The monoclonal antibodies segment accounted for the largest share of the global immunotherapy drugs market in 2019. This large share can be attributed to their high specificity and fewer side-effects, increasing focus on personalized medicines, initiatives by industry players, and the rising target disease incidence and patient pool On the basis of therapeutic area, this market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and other therapeutic areas. Cancer accounted for the largest share of the global immunotherapy drugs market, by therapeutic area, in 2019. The large share of this segment can be attributed to the growing prevalence of cancer, rising research activity in this area, and reimbursement coverage for immunotherapies for oncology."

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) BREAKING NEWS: Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") today announced that the National Institutes of Health has awarded Actinium a Small Business Technology Transfer grant to support a clinical collaboration with Memorial Sloan Kettering Cancer Center ("MSK") to study Iomab-ACT, Actinium's CD45-targeting Antibody Radio-Conjugate, for targeted conditioning to achieve lymphodepletion prior to administration of a CD19-targeted CAR T-cell therapy developed at MSK. The CD19 CAR-T has been previously studied by MSK in a Phase 2 trial with chemotherapy conditioning in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) or diffuse large B-cell lymphoma (DLBCL). MSK will lead this first of its kind study to utilize targeted radiopharmaceutical ARC-based lymphodepletion to replace chemotherapy-based conditioning prior to CAR T-cell therapy. The study will assess the feasibility of using Iomab-ACT targeted lymphodepletion prior to MSK's 19-28z CAR-T and assess safety and efficacy outcomes relative to results with MSK's CAR-T 19-28z in patients who had received chemotherapy-based lymphodepletion prior to CAR-T administration.

Results published in the New England Journal of Medicine with MSK's 19-28z CD19 CAR-T in 53 patients with R/R B-ALL reported complete remissions in 83% (44/53) of patients. Median event-free survival (EFS) was 6.1 months and median overall survival (OS) was 12.9 months at a median follow up period of 29 months (range 1 65 months) for all patients. Patients with low disease burden, defined as less than 5% blasts in the bone marrow, had markedly enhanced outcomes with increased median EFS of 10.6 months and median OS of 20.1 months. There was a 26% (14/53) rate of Grade 3 of greater cytokine release syndrome (CRS), with 1 patient death as a result, and 42% of patients experienced Grade 3-4 immune effector cell-associated neurotoxicity syndrome (ICANS). In addition to improved duration of response and survival, patients with low disease burden prior to receiving CAR T-cell therapy had lower rates of CRS and neurotoxicity.

"We are excited to be collaborating with MSK on this trial as they are aleader in the field of cellular therapies. We selected MSK's 19-28z CAR T-cell therapy for this NIH grant funded collaboration because ithas produced high response rates in patients with relapsed or refractory B-ALL who have previously undergone several lines of standard therapy. However, toxicities such as cytokine release syndrome and neurologic toxicity, as well as durability of response, remain a challenge as is the case with many other CAR T-cell therapies" commented Dr. Mark Berger, Actinium's Chief Medical Officer. "Iomab-ACT enables the delivery of targeted radiation that selectively and specifically targets immune cells, including those implicated in the CAR-T-associated toxicities of cytokine release syndrome and neurotoxicity. We are hopeful that this study will demonstrate improvements in safety and outcomes with MSK's CAR 19-28z as a result of Iomab-ACT targeted lymphodepletion and that this will allow clinicians to make important improvements in patients' ability to receive CAR T-cell therapies."

CAR-T is a type of cellular therapy in which a patient's own (autologous) T-cells are genetically engineered outside of the body to target the patient's cancer cells and which are then reinfused back into the patient to seek out and kill cancer cells. Currently there are 2 approved CD19 targeted CAR-T therapies, which both require chemotherapy-based conditioning to deplete the patient's lymphocytes, known as lymphodepletion, and many other CAR-T constructs in development that also use chemotherapy conditioning for lymphodepletion.

Iomab-ACT targets cells that express CD45, an antigen found on immune cells such as lymphocytes and macrophages as well as leukemia and lymphoma cancer cells and delivers the radioisotope warhead iodine-131 to achieve cell depletion. Iomab-ACT is intended to deplete CD45+ immune cells such as macrophages that are implicated in CAR-T related toxicities and may also have an anti-tumor effect on chemo-refractory cancers. Iomab-ACT is a low dose extension of Actinium's lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant. Preclinical data supporting Iomab-ACT's application in targeted lymphodepletion prior to ACT such as CAR-T was recently published in the journal Oncotarget (https://www.oncotarget.com/archive/v11/i39/). In addition, clinical data with trace doses of Iomab-B has shown transient, reversible lymphodepletion in patients and drug clearance pharmacokinetics that fit within the vein to vein time of CAR-T manufacturing and administration.

Sandesh Seth, Actinium's Chairman and CEO, said, "This clinical trial collaboration with MSK is a strong step forward for Actinium and our targeted conditioning program. The 19-28z CAR-T has already produced promising data and we look forward to working with MSK to explore Iomab-ACT's potential to reduce toxicities and improve patient outcomes. As we advance towards the SIERRA interim analysis in the fourth quarter, we are focused on the continued expansion of our ARC-based targeted conditioning program for bone marrow transplant and cell and gene therapies with the goal of providing targeted conditioning regimens that are less toxic and more effective than current chemotherapy-based conditioning. With these therapies being administered in a select number of concentrated centers, we see a large and growing market opportunity where our ARC-based targeted conditioning can improve outcomes and increase access to these important curative treatment options." Read this full release and more news for ATNM at: https://www.financialnewsmedia.com/news-atnm/

Other recent developments in the biotech industry include:

AstraZeneca PLC (NASDAQ: AZN) AstraZeneca's TAGRISSO(osimertinib) recently announced it has received acceptance for its supplemental New Drug Application (sNDA) and has also been granted Priority Review in the US for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years.

Bristol Myers Squibb (NYSE:BMY) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval ofOpdivo(nivolumab) for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based combination chemotherapy. The European Commission (EC), which is authorized to approve medicines for the European Union (EU), will now review the CHMP recommendation.

"This positive CHMP opinion underscores the potential ofOpdivoin the EU treatment landscape for esophageal squamous cell carcinoma, with the ATTRACTION-3 trial showing clinically meaningful survival coupled with a favorable safety profile," said Ian M. Waxman, M.D., development lead, gastrointestinal cancers, Bristol Myers Squibb. "We look forward to the EC's final decision, which could mark the first time an immunotherapy is approved for any upper gastrointestinal cancer in the EU. We remain committed to continuing to explore the potential benefits ofOpdivoin earlier settings of esophageal cancer."

Merck (NYSE: MRK), known as MSD outside the United States and Canada, recently announced findings from two additional Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the company's investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age or older received V114 or PCV13 followed by PNEUMOVAX23 one year later. Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13 (day 30), immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination. Results from both studies are based on opsonophagocytic activity (OPA) responses a measure of vaccine-induced functional antibodies. V114 was generally well tolerated in both studies, with a safety profile consistent with that observed for V114 in previously reported studies.

Northwest Biotherapeutics(OTCQB: NWBO), a biotechnology company developing DCVaxpersonalized immune therapies for solid tumor cancers, recently announced that the database for the Phase III trial of DCVax-L for Gliobastoma has been locked. With the database now locked, the independent service firms managing the Clinical Trial are arranging for the independent statisticians to have access to the unblinded raw data from the Trial. Neither the Company nor any party other than the independent statisticians will have access to any unblinded data at this stage.

The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty five hundred dollars for news coverage of the current press releases issued by Actinium Pharmaceuticals, Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:

Media Contact email:[emailprotected] -+1(561)325-8757

SOURCE Financialnewsmedia.com

View original post here:
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market - PRNewswire

BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will participate in 8th annual Chief Medical Officer Summit 360, being held virtually on October 26-27, 2020.

Breakout Session Details: Title: Tracking Personalized Medications in Gene and Cell TherapyDate/Time: October 26, 2020 at 3:00 p.m.

For more information on the 8th annual CMO Summit 360, or to register, please click here.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first- in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage in patients with COVID-19 who are experiencing respiratory failure, for which the Company recently initiated a clinical trial as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2a clinical trial in the U.S. and slated to begin a comprehensive Phase 2b trial in the U.S. during 4Q20 for the treatment of coronary microvascular dysfunction (CMD); and CLBS14, a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA). For more information on the company, please visit http://www.caladrius.com.

Contact:

Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone:+1-908-842-0084Email:jmenditto@caladrius.com

Media:W2O GroupChristiana PascalePhone: +1-212-257-6722Email:cpascale@w2ogroup.com

Go here to read the rest:
Caladrius Biosciences to Participate in the 8th Annual Chief Medical Officer Summit 360 - GlobeNewswire

GeekWire Summit panelists, clockwise from top left: Threshold co-founder Emily Melton; Canaan Partners general partner Nina Kjellson; and Biomatics Capital co-founder Julie Sunderland.

Investor interest in healthcare technology is on the rise amid a pandemic that has put a spotlight on telemedicine, patient monitoring, and more. Global VC funding to digital health companies reached a record $10.3 billion through the first nine months of this year, up 43% year-over-year, according to Mercom Capital Group.

At the GeekWire Summit on Tuesday, we brought together three investors who are spending time at the crossroads of technology and healthcare. Read on for takeaways from the conversation, which included Threshold co-founder Emily Melton, Biomatics Capital co-founder Julie Sunderland, and Canaan Partners general partner Nina Kjellson. Dr. Robert Overell, president of Foundation BioVenture, moderated the discussion.

No slowdown: Nearly all industries braced for the worst when COVID-19 began spreading. But the investors agreed that activity within the healthcare tech market is now accelerating. Sunderland called out the progress being made with COVID-19 therapeutics and vaccines, as well as advances with telemedicine and remote care.

Its been a good signal of the thesis we all have, which is that we live at an extraordinary time in terms of innovation in biopharma and innovation in the application of technology to healthcare, Sunderland said.

Melton added: We are not seeing a slowdown now. If anything, its actually faster than its ever been and one of the most competitive markets Ive ever been involved in.

Holy grail:As remote care becomes more common, collecting reliable data from patients outside the clinic or hospital and making it seamless will be paramount. Kjellson called it the holy grail of remote care.

Whether its for clinical use to practice better medicine, or for clinical trials to get better data, that is a trend accelerated by COVID and is here to stay and will drive value going forward, she said. From an investment basis, if we can improve that reliably, we should be looking for those opportunities and investing in those opportunities. It will make better medicines, it will drive better clinical trials, its good for the healthcare system.

Melton said thats particularly true if the right value-based incentive business models are also put in place so people are encouraged to participate in the data collection process.

Sunderland said shes excited about using data to drive behavior change, but the lack of payment mechanisms is a roadblock to capturing value and building new businesses.

When you run into that wall of trying to sell tools into the payer system, and you realize how hard it is and how long those enterprise cycles are and how hard it is to get to scale even if you were creating value from patients, you get discouraged pretty quickly, she said.

Not just computers for healthcare: The relationship between tech and healthcare is rapidly evolving as digital tools and services are applied across various sectors.

Melton called out Livongo, the digital disease management company that announced its $18.5 billion acquisition by Teladoc Health in August. The Livongo solution includes both hardware such as monitoring devices, and software that provides data insights and enables patient communication.

We get excited about those intersections, said Melton, whose firm invested in Livongo. Its not just thinking about only investing in software companies or services businesses or medical devices companies, but looking at where to bring those pieces together to create unique experiences that drive more value.

Kjellson added that many biotech companies are now built on the power of informatics, whether its processing data or doing faster DNA sequencing. She also brought up Vineti, which sells software that helps manage the supply chain and manufacturing process for biotech firms developing personalized treatments. The company counts both Threshold and Canaan Partners as investors.

Vineti is trying to be the enterprise solution to modernize how you connect all of these nodes from the couriers to clinicians to the manufacturers so you have a really safe, seamless, transparent process for how precision medicine gets delivered to patients, Kjellson said. Thats a very different way of thinking about health IT than computers for healthcare.'

[The full interview with the healthtech investors, and other GeekWire Summit sessions, are available on-demand exclusively to attendees of the virtual event.Learn more and register here.]

Read the rest here:
Healthtech investors on the holy grail of remote care and a new way of thinking about health IT - GeekWire